Aquestive Therapeutics (AQST) reported $11.87 million in revenue for the quarter ended December 2024, representing a year-over-year decline of 10.2%. EPS of -$0.19 for the same period compares to ...
Aquestive Therapeutics: Robust Development Of Oral Emergency Therapies Will Likely Pay Off Into 2025
Aquestive Therapeutics shares surged 137.29% (YoY) after FDA approval of rival company ARS Pharmaceutical's "epinephrine nasal spray" Neffy. Market optimism surrounds AQST’s robust R&D pipeline, with ...
We recently published a list of 10 Best Multibagger Stocks To Buy Heading into 2025. In this article, we are going to take a look at where Aquestive Therapeutics, Inc. (NASDAQ:AQST) stands against ...
Detailed price information for Aquestive Therapeutics Inc (AQST-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results